Erin E Crotty, MD

Erin E Crotty, MD

Cancer and Blood Disorders Center, Brain Tumor Program, Neuro-Oncology, Solid Tumors Oncology

On staff since July 2020

Children's Title: Attending Physician, Pediatric Hematology/Oncology and Bone Marrow Transplant

Academic Title: Assistant Professor, Hematology-Oncology

Research Center: Ben Towne Center for Childhood Cancer Research

  • Erin Crotty, M.D. is an Attending Physician at Seattle Children's Hospital and Assistant Professor at the University of Washington School of Medicine. She cares for children and adolescents with brain and spinal cord tumors, in addition to leading the Retinoblastoma Program with oncologic ophthalmologist, Dr. Andrew Stacey. Dr. Crotty completed her pediatric residency training at Children's National Medical Center in Washington, D.C. and returned home to the west coast for fellowship in hematology/oncology at Seattle Children's Hospital/University of Washington. She holds board certifications in pediatrics and pediatric hematology/oncology.

    • Related Pages

    • The Olson Lab

      The Olson lab identifies, prioritizes, and advances therapeutics into clinical trials for children with brain cancer, with increasing focus on types of brain tumors that are uncommon and have the greatest need for translational research.

    • Emma Seattle 03.30.21

      Dr. Crotty is an incredible doctor who treats not only our son, but our entire family, with the utmost care and respect. She became our primary oncologist shortly after joining Seattle Children's brain tumor team and I could not believe we got so lucky to be connected with her when our son was diagnosed with brain cancer. She has helped us navigate the most difficult conversations and decisions with expert information, thorough explanation, and so much compassion. I couldn't recommend Dr. Crotty more for her expertise and caring nature.

  • Award Name Award Description Awarded By Award Date
    2022 Emerging Scientist Award Children's Cancer Research Fund Oct. 2022 - Oct. 2023
    Clinical Scholars Research Program Seattle Children's Research Institute Oct. 2021 - Oct. 2023
    Resident Teaching Award Children's National Medial Center 2015 - 2017
    Gill Fellowship Research Award George Washington University 2011
  • Other Publications

    • Crotty E, Gust J
      Pediatric ependymoma: New perspectives on older trials.
      35325202 Neuro-oncology, 2022 June 1 : 24(6)949-950 PMCID:PMC9159413
    • Crotty E, Gust J
      Pediatric ependymoma: New perspectives on older trials.
      35325202 Neuro-oncology, 2022 June 1 : 24(6)949-950 PMCID:PMC9159413
    • Crotty E, Gust J
      Pediatric ependymoma: New perspectives on older trials.
      35325202 Neuro-oncology, 2022 June 1 : 24(6)949-950 PMCID:PMC9159413
    • Ohlsen TJD, Scanlon S, Perez FA, Ermoian RP, Paulson VA, Hauptman JS, Crotty EE, Ting MA
      Synchronous rare tumors in a pediatric patient with a de novo cancer predisposition syndrome.
      35484874 Pediatric blood & cancer, 2022 April 28 : e29746
    • Ohlsen TJD, Scanlon S, Perez FA, Ermoian RP, Paulson VA, Hauptman JS, Crotty EE, Ting MA
      Synchronous rare tumors in a pediatric patient with a de novo cancer predisposition syndrome.
      35484874 Pediatric blood & cancer, 2022 April 28 : e29746
    • Ohlsen TJD, Scanlon S, Perez FA, Ermoian RP, Paulson VA, Hauptman JS, Crotty EE, Ting MA
      Synchronous rare tumors in a pediatric patient with a de novo cancer predisposition syndrome.
      35484874 Pediatric blood & cancer, 2022 April 28 : e29746
    • Mustafi D, Waligorski N, Paulson V, Cole B, Crotty EE, Stacey AW
      Pineoblastoma Without Retinal Tumors in a Patient With a Mosaic Retinoblastoma Pathogenic Variant.
      35297960 JAMA ophthalmology, 2022 April 1 : 140(4)437-439
    • Mustafi D, Waligorski N, Paulson V, Cole B, Crotty EE, Stacey AW
      Pineoblastoma Without Retinal Tumors in a Patient With a Mosaic Retinoblastoma Pathogenic Variant.
      35297960 JAMA ophthalmology, 2022 April 1 : 140(4)437-439
    • Scherpelz KP, Crotty EE, Paulson VA, Lockwood CM, Leary SES, Ellenbogen RG, Lee A, Ermoian RP, Vitanza NA, Cole BL
      Two cases of pineal anlage tumor with molecular analysis.
      35129878 Pediatric blood & cancer, 2022 April : 69(4)e29596
    • Mustafi D, Waligorski N, Paulson V, Cole B, Crotty EE, Stacey AW
      Pineoblastoma Without Retinal Tumors in a Patient With a Mosaic Retinoblastoma Pathogenic Variant.
      35297960 JAMA ophthalmology, 2022 April 1 : 140(4)437-439
    • Scherpelz KP, Crotty EE, Paulson VA, Lockwood CM, Leary SES, Ellenbogen RG, Lee A, Ermoian RP, Vitanza NA, Cole BL
      Two cases of pineal anlage tumor with molecular analysis.
      35129878 Pediatric blood & cancer, 2022 April : 69(4)e29596
    • Scherpelz KP, Crotty EE, Paulson VA, Lockwood CM, Leary SES, Ellenbogen RG, Lee A, Ermoian RP, Vitanza NA, Cole BL
      Two cases of pineal anlage tumor with molecular analysis.
      35129878 Pediatric blood & cancer, 2022 April : 69(4)e29596
    • Crumm CE, Crotty EE, Albert CM, Blair AB, Otjen JP, Feldman KW
      Atraumatic Spinal Epidural Hematoma as Initial Presentation of Hemophilia A in an Infant.
      30870339 Pediatric emergency care, 2021 Nov. 1 : 37(11)e772-e774
    • Crumm CE, Crotty EE, Albert CM, Blair AB, Otjen JP, Feldman KW
      Atraumatic Spinal Epidural Hematoma as Initial Presentation of Hemophilia A in an Infant.
      30870339 Pediatric emergency care, 2021 Nov. 1 : 37(11)e772-e774
    • Crumm CE, Crotty EE, Albert CM, Blair AB, Otjen JP, Feldman KW
      Atraumatic Spinal Epidural Hematoma as Initial Presentation of Hemophilia A in an Infant.
      30870339 Pediatric emergency care, 2021 Nov. 1 : 37(11)e772-e774
    • Crotty EE, Smith SMC, Brasel K, Pakiam F, Girard EJ, Connor YD, Zindy F, Mhyre AJ, Roussel MF, Olson JM
      Medulloblastoma recurrence and metastatic spread are independent of colony-stimulating factor 1 receptor signaling and macrophage survival.
      33963961 Journal of neuro-oncology, 2021 June : 153(2)225-237 PMCID:PMC8248272
    • Crotty EE, Smith SMC, Brasel K, Pakiam F, Girard EJ, Connor YD, Zindy F, Mhyre AJ, Roussel MF, Olson JM
      Medulloblastoma recurrence and metastatic spread are independent of colony-stimulating factor 1 receptor signaling and macrophage survival.
      33963961 Journal of neuro-oncology, 2021 June : 153(2)225-237 PMCID:PMC8248272
    • Crotty EE, Smith SMC, Brasel K, Pakiam F, Girard EJ, Connor YD, Zindy F, Mhyre AJ, Roussel MF, Olson JM
      Medulloblastoma recurrence and metastatic spread are independent of colony-stimulating factor 1 receptor signaling and macrophage survival.
      33963961 Journal of neuro-oncology, 2021 June : 153(2)225-237 PMCID:PMC8248272
    • Crotty EE, Smith SMC, Brasel K, Pakiam F, Girard EJ, Connor YD, Zindy F, Mhyre AJ, Roussel MF, Olson JM
      Medulloblastoma recurrence and metastatic spread are independent of colony-stimulating factor 1 receptor signaling and macrophage survival.
      33963961 Journal of neuro-oncology, 2021 June : 153(2)225-237 PMCID:PMC8248272
    • Crotty EE, Smith SMC, Brasel K, Pakiam F, Girard EJ, Connor YD, Zindy F, Mhyre AJ, Roussel MF, Olson JM
      Medulloblastoma recurrence and metastatic spread are independent of colony-stimulating factor 1 receptor signaling and macrophage survival.
      33963961 Journal of neuro-oncology, 2021 June : 153(2)225-237 PMCID:PMC8248272
    • Crotty E, Downey K, Ferrerosa L, Flores C, Hegde B, Raskin S, Hwang E, Vitanza N, Okada H
      Considerations when treating high-grade pediatric glioma patients with immunotherapy.
      33225764 Expert review of neurotherapeutics, 2021 Feb. : 21(2)205-219 PMCID:PMC7880880
    • Crotty E, Downey K, Ferrerosa L, Flores C, Hegde B, Raskin S, Hwang E, Vitanza N, Okada H
      Considerations when treating high-grade pediatric glioma patients with immunotherapy.
      33225764 Expert review of neurotherapeutics, 2021 Feb. : 21(2)205-219 PMCID:PMC7880880
    • Crotty E, Downey K, Ferrerosa L, Flores C, Hegde B, Raskin S, Hwang E, Vitanza N, Okada H
      Considerations when treating high-grade pediatric glioma patients with immunotherapy.
      33225764 Expert review of neurotherapeutics, 2021 Feb. : 21(2)205-219 PMCID:PMC7880880
    • Crotty E, Downey K, Ferrerosa L, Flores C, Hegde B, Raskin S, Hwang E, Vitanza N, Okada H
      Considerations when treating high-grade pediatric glioma patients with immunotherapy.
      33225764 Expert review of neurotherapeutics, 2020 Dec. 17 : 1-15
    • Crotty EE, Leary SES, Geyer JR, Olson JM, Millard NE, Sato AA, Ermoian RP, Cole BL, Lockwood CM, Paulson VA, Browd SR, Ellenbogen RG, Hauptman JS, Lee A, Ojemann JG, Vitanza NA
      Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
      32556862 Journal of neuro-oncology, 2020 July : 148(3)607-617
    • Crotty EE, Leary SES, Geyer JR, Olson JM, Millard NE, Sato AA, Ermoian RP, Cole BL, Lockwood CM, Paulson VA, Browd SR, Ellenbogen RG, Hauptman JS, Lee A, Ojemann JG, Vitanza NA
      Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
      32556862 Journal of neuro-oncology, 2020 July : 148(3)607-617
    • Crotty EE, Leary SES, Geyer JR, Olson JM, Millard NE, Sato AA, Ermoian RP, Cole BL, Lockwood CM, Paulson VA, Browd SR, Ellenbogen RG, Hauptman JS, Lee A, Ojemann JG, Vitanza NA
      Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
      32556862 Journal of neuro-oncology, 2020 July : 148(3)607-617
    • Crotty EE, Leary SES, Geyer JR, Olson JM, Millard NE, Sato AA, Ermoian RP, Cole BL, Lockwood CM, Paulson VA, Browd SR, Ellenbogen RG, Hauptman JS, Lee A, Ojemann JG, Vitanza NA
      Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
      32556862 Journal of neuro-oncology, 2020 July : 148(3)607-617
    • Crumm CE, Crotty EE, Albert CM, Blair AB, Otjen JP, Feldman KW
      Atraumatic Spinal Epidural Hematoma as Initial Presentation of Hemophilia A in an Infant.
      30870339 Pediatric emergency care, 2019 March 12
    • Crotty EE, Meier ER, Wells EM, Hwang EI, Packer RJ
      Anaplastic Ependymoma in a Child With Sickle Cell Anemia: A Case Report Highlighting Treatment Challenges for Young Children With Central Nervous System Tumors and Underlying Vasculopathy.
      26488903 Pediatric blood & cancer, 2016 March : 63(3)547-50
    • Crotty EE, Meier ER, Wells EM, Hwang EI, Packer RJ
      Anaplastic Ependymoma in a Child With Sickle Cell Anemia: A Case Report Highlighting Treatment Challenges for Young Children With Central Nervous System Tumors and Underlying Vasculopathy.
      26488903 Pediatric blood & cancer, 2016 March : 63(3)547-50
    • Crotty EE, Meier ER, Wells EM, Hwang EI, Packer RJ
      Anaplastic Ependymoma in a Child With Sickle Cell Anemia: A Case Report Highlighting Treatment Challenges for Young Children With Central Nervous System Tumors and Underlying Vasculopathy.
      26488903 Pediatric blood & cancer, 2016 March : 63(3)547-50
    • Crotty EE, Meier ER, Wells EM, Hwang EI, Packer RJ
      Anaplastic Ependymoma in a Child With Sickle Cell Anemia: A Case Report Highlighting Treatment Challenges for Young Children With Central Nervous System Tumors and Underlying Vasculopathy.
      26488903 Pediatric blood & cancer, 2016 March : 63(3)547-50

  • Grant Title Grantor Amount Award Date
    2022 Emerging Scientist Award Children's Cancer Research Fund 2022 - 2023
    Clinical Research Scholars Program (CRSP) Award Center for Clinical and Translational Research Oct. 2021 - Oct. 2023
    The Childhood Brain Tumor Foundation Research Grant The Childhood Brain Tumor Foundation July 2020 - July 2022
    NIH 5T32CA009351 Ruth L. Kirschstein Research Service Award NIH July 2018 - July 2020

Overview

Board Certification(s)

Pediatric Hematology-Oncology
Pediatrics

Residency

Children's National Medical Center, Washington, DC

Fellowship

University of Washington School of Medicine GME, Seattle, WA

Research Description

Dr. Crotty's research interests include immuno-oncology and precision medicine approaches for children with central nervous system (CNS) tumors. Dr. Crotty is particularly interested in the translation of promising therapies from the lab bench into innovative clinical trials for patients. She collaborates with international cancer consortium members in the design and implementation of clinical research.

Dr. Crotty's prior work in the Olson Laboratory at the Fred Hutchinson Cancer Center (now located at Seattle Children's Research Institute) studying novel immunotherapy for medulloblastoma provided the preclinical foundation for an upcoming consortium-led Phase I clinical trial. In 2022, she was awarded the Children's Cancer Research Fund Emerging Scientist Award to study a novel cell-free DNA sequencing technique to reliably detect residual disease left over after treatment in the cerebrospinal fluid (CSF). For children with brain tumors, this platform could enable personalized treatment with reduced toxicity. 

Research Focus Area

Retinoblastoma, Brain tumor, Immunotherapy, CAR-T cells